Dose-dependence of protection from systemic reactions to venom immunotherapy by omalizumab

BACKGROUND: Systemic reactions (SR) to venom immunotherapy (VIT) are rare but may occur, with a rate significantly higher for honeybee than for vespid VIT. In patients with repeated SRs to VIT it is difficult to reach the maintenance dose of venom and pre-treatment with omalizumab is indicated, as s...

Descripción completa

Detalles Bibliográficos
Autores principales: Boni, Elisa, Incorvaia, Cristoforo, Mauro, Marina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5078942/
https://www.ncbi.nlm.nih.gov/pubmed/27799850
http://dx.doi.org/10.1186/s12948-016-0051-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5078942/
https://www.ncbi.nlm.nih.gov/pubmed/27799850
http://dx.doi.org/10.1186/s12948-016-0051-2

Ejemplares similares